Search

Your search keyword '"Fung, Chunkit"' showing total 335 results
Start Over Author "Fung, Chunkit"
335 results on '"Fung, Chunkit"'

51. Impact of cisplatin-induced hearing loss (CIHL) on patient-reported social and emotional functioning.

Author

Sanchez, Victoria, primary, Shuey, Megan, additional, Dinh, Paul C., additional, Monahan, Patrick, additional, Sesso, Howard D., additional, Dolan, Mary Eileen, additional, Fossa, Sophie D., additional, Einhorn, Lawrence H., additional, Vaughn, David J., additional, Martin, Neil E., additional, Fung, Chunkit, additional, Frisina, Robert D., additional, and Travis, Lois B., additional

Published
2022
Full Text
View/download PDF

52. Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment.

Author

Nakshatri, Swetha, primary, Shuey, Megan, additional, Shahbazi, Mohammad, additional, Trendowski, Matthew, additional, Dinh, Paul C., additional, Feldman, Darren R., additional, Hamilton, Robert James, additional, Vaughn, David J., additional, Fung, Chunkit, additional, Kollmannsberger, Christian K., additional, Einhorn, Lawrence, additional, Frisina, Robert D., additional, Travis, Lois B., additional, Dolan, Mary Eileen, additional, and Cox, Nancy, additional

Published
2022
Full Text
View/download PDF

54. A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.

Author

Kilari, Deepak, primary, Szabo, Aniko, additional, Tripathi, Abhishek, additional, Paul, Asit K., additional, Alter, Robert S., additional, Bylow, Kathryn A., additional, Nelson, Ariel Ann, additional, Hall, William A., additional, Langenstroer, Peter, additional, Jacobsohn, Kenneth, additional, Rini, Brian I., additional, Van Veldhuizen, Peter J., additional, Johnson, Scott, additional, Davis, Nancy B., additional, Fung, Chunkit, additional, and Milowsky, Matthew I., additional

Published
2022
Full Text
View/download PDF

58. Comprehensive association analysis of speech recognition thresholds after cisplatin‐based chemotherapy in survivors of adult‐onset cancer.

Author

Shahbazi, Mohammad, Zhang, Xindi, Dinh, Paul C., Sanchez, Victoria A., Trendowski, Matthew R., Shuey, Megan M., Nguyen, Tessa, Feldman, Darren R., Vaughn, David J., Fung, Chunkit, Kollmannsberger, Christian, Martin, Neil E., Einhorn, Lawrence H., Cox, Nancy J., Frisina, Robert D., Travis, Lois B., and Dolan, Mary Eileen

Subjects
SPEECH perception, CANCER survivors, HEARING disorders, GENETIC variation, SMOKING statistics, MOTOR neuron diseases, SPEECH-language pathology, SPEECH apraxia
Abstract

Purpose: Deficits in speech understanding constitute one of the most severe consequences of hearing loss. Here we investigate the clinical and genetic risk factors for symmetric deterioration of speech recognition thresholds (SRT) among cancer survivors treated with cisplatin. Methods: SRT was measured using spondaic words and calculating the mean of measurements for both ears with symmetric SRT values. For clinical associations, SRT‐based hearing disability (SHD) was defined as SRT≥15 dB hearing loss and clinical variables were derived from the study dataset. Genotyped blood samples were used for GWAS with rank‐based inverse normal transformed SRT values as the response variable. Age was used as a covariate in association analyses. Results: SHD was inversely associated with self‐reported health (p = 0.004). Current smoking (p = 0.002), years of smoking (p = 0.02), BMI (p < 0.001), and peripheral motor neuropathy (p = 0.003) were positively associated with SHD, while physical activity was inversely associated with SHD (p = 0.005). In contrast, cumulative cisplatin dose, peripheral sensory neuropathy, hypertension, and hypercholesterolemia were not associated with SHD. Although no genetic variants had an association p value < 5 × 10−8, 22 genetic variants were suggestively associated (p < 10−5) with SRT deterioration. Three of the top variants in 10 respective linkage disequilibrium regions were either positioned within the coding sequence or were eQTLs for genes involved in neuronal development (ATE1, ENAH, and ZFHX3). Conclusion: Current results improve our understanding of risk factors for SRT deterioration in cancer survivors. Higher BMI, lower physical activity, and smoking are associated with SHD. Larger samples would allow for expansion of the current findings on the genetic architecture of SRT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

59. A nationwide double-blind phase III randomized clinical trial (RCT) of olanzapine vs. prochlorperazine for the treatment of refractory nausea in patients receiving moderately or highly emetogenic chemotherapy among NCI Community Oncology Research Program (NCORP) practices

Author

Peppone, Luke Joseph, Fung, Chunkit, Guido, Joseph John, Morrow, Gary R., Janelsins, Michelle Christine, Yost, Kathleen J., Firwana, Belal, Roscoe, Joseph, and Culakova, Eva

Subjects
OLANZAPINE, TREATMENT effectiveness, CONFERENCES & conventions, PROCHLORPERAZINE, CANCER chemotherapy, DRUG efficacy, NAUSEA, EVALUATION
Abstract

185 Background: Despite advances in antiemetics given during chemotherapy, nausea remains a clinically significant issue and greatly impairs quality of life (QOL). Current ASCO guidelines recommend olanzapine or prochlorperazine for refractory chemotherapy-induced nausea. However, there is a lack of direct empirical comparisons to establish their relative efficacy. Methods: The URCC NCORP Research Base and 21 NCORP practices enrolled 1,363 chemotherapy-naïve patients with breast cancer starting a high/moderate emetogenic chemotherapy regimen to this Phase III RCT (NCT03367572). Antiemetics were prescribed per ASCO guidelines. Screening occurred during Cycle 1, followed by randomization for Cycle 2. Those with ≥ moderate nausea (≥3 on a 1-7 scale) in Cycle 1 and willing to continue were randomized (1:1:1 ratio) into 3 arms (n=310): 1) ASCO regimen plus olanzapine (OLZ), 2) ASCO regimen plus prochlorperazine (PC), or 3) ASCO regimen plus placebo. Nausea was evaluated using a four-day home diary (4x daily), with the primary outcomes being changes in average (avg) and maximum (max) nausea. FACT-G measured QOL. Intent-to-treat primary analyses (ANOVA and Cohen's Δ effect size) evaluated whether OLZ or PC improved nausea, testing between-arm differences in nausea change from Cycle 1 to 2 compared to placebo at a p=0.025 significance level corrected for 3 arms. Results: The median age was 50.7y, with 80.7% White/12.3% Black/5.8% Asian/4.2% Latino, and evenly distributed across groups. The change in avg nausea score was statistically significant for the OLZ (avg change = −1.07: Cohen's Δ = 0.49) and PC arms (avg change = −0.94: Cohen's Δ = 0.38) compared to the placebo (avg change = −0.50; p <0.001 vs OLZ, p = 0.01 vs PC). Similar but larger changes were noted for change in max nausea score in the OLZ (max change = −2.57: Cohen's Δ = 0.86) and PC arms (max change = −2.01: Cohen's Δ = 0.47) against the placebo (max change = −1.30; p <0.001 vs OLZ, p <0.01 vs PC). The OLZ arm had a clinically significant change in overall QOL from pre-chemo to Cycle 2 vs placebo (FACT-G mean difference = +4.91; p = 0.006) but the PC arm vs placebo did not (FACT-G mean difference = −0.87; p = 0.61). OLZ exhibited superiority over PC in terms of changes in max nausea (mean difference = −0.56; p = 0.023) and QOL (FACT-G mean difference = +5.80; p = 0.006), but not for avg nausea (mean difference = −0.13; p = 0.418). Conclusions: OLZ and PC, when added to ASCO guidelines, each significantly reduces refractory nausea. OLZ demonstrates superior max nausea control with clinically and statistically significant improvements in QOL. This study fills the gap in empirical comparisons and solidifies OLZ's position as a promising intervention for refractory nausea. Clinical trial information: NCT03367572. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

65. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Powles, Thomas, primary, Csőszi, Tibor, additional, Özgüroğlu, Mustafa, additional, Matsubara, Nobuaki, additional, Géczi, Lajos, additional, Cheng, Susanna Y-S, additional, Fradet, Yves, additional, Oudard, Stephane, additional, Vulsteke, Christof, additional, Morales Barrera, Rafael, additional, Fléchon, Aude, additional, Gunduz, Seyda, additional, Loriot, Yohann, additional, Rodriguez-Vida, Alejo, additional, Mamtani, Ronac, additional, Yu, Evan Y, additional, Nam, Kijoeng, additional, Imai, Kentaro, additional, Homet Moreno, Blanca, additional, Alva, Ajjai, additional, Cascallar, Diana Vera, additional, Varela, Mirta, additional, Lazzaro, Mauricio Fernandez, additional, Kaen, Diego Lucas, additional, Gatica, Gabriela, additional, Flores, David Hugo, additional, Falco, Agustin, additional, Molina, Matias, additional, Van Aelst, Filip, additional, Sautois, Brieuc, additional, Machiels, Jean-Pascal, additional, Schallier, Denis, additional, Brust, Leandro, additional, Rapatoni, Liane, additional, Azevedo, Sergio J, additional, Marinho, Gisele, additional, Soares, Joao Paulo Holanda, additional, Dzik, Carlos, additional, Almeida Silva, Jamile, additional, Fay, Andre Poisl, additional, Gingerich, Joel, additional, Ferrario, Cristiano, additional, Potvin, Kylea, additional, Vanhuyse, Marie, additional, Abdelsalam, Mahmoud, additional, Cheng, Susanna, additional, Caglevic, Christian, additional, Reyes, Felipe, additional, Leal, Jose Luis, additional, Francisco, Francisco, additional, Ibanez, Carolina, additional, Joly, Florence, additional, Laguerre, Brigitte, additional, Ladoire, Sylvain, additional, Flechon, Aude, additional, Topart, Delphine, additional, Huillard, Olivier, additional, Oudard, Stéphane, additional, Gross-Goupil, Marine, additional, Culine, Stephane, additional, Gravis, Gwenaelle, additional, Reichardt, Peter, additional, Retz, Margitta, additional, Herden, Jan, additional, Pfister, David, additional, Ohlman, Carsten, additional, Stoeckle, Michael, additional, Wirth, Manfred, additional, Lorch, Anja, additional, Niegisch, Guenter, additional, Goebell, Peter J, additional, Boegemann, Martin, additional, Merseburger, Axel, additional, Gakis, Georgios, additional, Bedke, Jens, additional, Neisius, Andreas, additional, Thomas, Christian, additional, Hoefner, Thomas, additional, Telekes, Andras, additional, Kosa, Judit Erzsebet, additional, Revesz, Janos, additional, Bodoky, Gyorgy, additional, Csoszi, Tibor, additional, Csejtei, Andras, additional, Geczi, Lajos, additional, Ruzsa, Agnes, additional, Kolonics, Zsuzsanna, additional, Erfan, Jozsef, additional, McDermott, Ray, additional, Bambury, Richard, additional, Sella, Avishay, additional, Frank, Stephen Jay, additional, Kejzman, Daniel, additional, Goldman, Olesya, additional, Rosenbaum, Eli, additional, Peer, Avivit, additional, Berger, Raanan, additional, Rouvinov, Keren, additional, Sarid, David, additional, Fukasawa, Satoshi, additional, Arai, Gaku, additional, Yamaguchi, Akito, additional, Yokomizo, Akira, additional, Takayama, Tatsuya, additional, Kinoshita, Hidefumi, additional, Kikuchi, Eiji, additional, Mizuno, Ryuichi, additional, Fujii, Yasuhisa, additional, Sassa, Naoto, additional, Matsukawa, Yoshihisa, additional, Fujimoto, Kiyohide, additional, Tanikawa, Toshiki, additional, Tomita, Yoshihiko, additional, Nishimura, Kazuo, additional, Tsujihata, Masao, additional, Oyama, Masafumi, additional, Masumori, Naoya, additional, Kanayama, Hiroomi, additional, Takano, Toshimi, additional, Miura, Yuji, additional, Miyazaki, Jun, additional, Joraku, Akira, additional, Kimura, Tomokazu, additional, Yamamoto, Yoshiaki, additional, Kobayashi, Kazuki, additional, De Wit, Ronald, additional, Aarts, Maureen, additional, Gerritsen, Winald, additional, Los, Maartje, additional, Beerepoot, Laurens, additional, Izmailov, Adel, additional, Gorelov, Sergey Igorevich, additional, Alekseev, Boris Yakovlevich, additional, Semenov, Andrey, additional, Kostorov, Vladimir Anatolyevich, additional, Alekseev, Sergey M, additional, Zyryanov, Alexander, additional, Oschepkov, Vasiliy Nikolaevich, additional, Shidin, Vladimir Aleksandrovich, additional, Vladimirov, Vladimir Ivanovich, additional, Gafanov, Rustem Airatovich, additional, Karlov, Petr Alexandrovich, additional, Anderson, David Brian, additional, Shepherd, Lucinda, additional, Cohen, Graham Lawrence, additional, Rapoport, Bernardo Louis, additional, Ruff, Paul, additional, Lee, Nari, additional, Bae, Woo Kyun, additional, Lee, Hyo Jin, additional, Herranz, Urbano Anido, additional, Grande, Enrique, additional, Alonso Gordoa, Teresa, additional, Guma Padro, Josep, additional, Gauna, Daniel Castellano, additional, Arranz, Jose Angel, additional, Munoz Langa, Jose, additional, Sarrio, Regina Girones, additional, Montesa Pino, Alvaro, additional, Juan Fita, Maria Jose, additional, Su, Yu-Li, additional, Lin, Yung-Chang, additional, Su, Wen-Pin, additional, Shen, Ying-Chun, additional, Chang, Yen-Hwa, additional, Huang, Yi-Hsiu, additional, Sriuranpong, Virote, additional, Chansriwong, Phichai, additional, Srimuninnimit, Vichien, additional, Danchaivijitr, Pongwut, additional, Abali, Huseyin, additional, Yavuz, Sinan, additional, Ozyilkan, Ozgur, additional, Sendur, Mehmet Ali Nahit, additional, Ekenel, Meltem, additional, Ozguroglu, Mustafa, additional, Arslan, Cagatay, additional, Ozdogan, Mustafa, additional, Birtle, Alison, additional, Powles, Thomas, additional, Huddart, Robert, additional, de Santis, Maria, additional, Zarkar, Anjali, additional, Evans, Linda, additional, Hussain, Syed, additional, DiSimone, Christopher, additional, Muina, Antonio F, additional, Schlegel, Peter, additional, Jhangiani, Haresh S, additional, Harrison, Michael, additional, Slater, Dennis E, additional, Wright, David, additional, Percent, Ivor J, additional, Lin, Jianqing, additional, Hwang, Clara, additional, Gupta, Sumati, additional, Bajaj, Madhuri, additional, Galamaga, Robert, additional, Eklund, John, additional, Wallace, James, additional, Shtivelband, Mikhail, additional, Suh, Jason Jung-Gon, additional, Burhani, Nafisa, additional, Eadens, Matthew, additional, Gunturu, Krishna, additional, Burgess, Earle, additional, Wong, John, additional, Chaudhry, Arvind, additional, Van Veldhuizen, Peter, additional, Graff, Stephanie, additional, Thomas, Christian A, additional, Schnadig, Ian D, additional, Carneiro, Benedito, additional, Hussain, Maha, additional, Morgans, Alicia, additional, Fitzharris, John T, additional, Oliff, Ira A, additional, Vuky, Jacqueline, additional, Hauke, Ralph, additional, Baron, Ari, additional, Joshi, Monika, additional, Bolemon, Britt H, additional, Jiang, Peter, additional, Mega, Anthony E, additional, Markus, Maurice, additional, Pfanzelter, Nicklas, additional, Lawler, William Eyre, additional, Cobb, Patrick Wayne, additional, Courtright, Jay G, additional, Jain, Sharad, additional, Doshi, Gurjyot, additional, Gunuganti, Vijay K, additional, Sartor, Oliver Alton, additional, Cole, Scott W, additional, Babiker, Hani, additional, Uchio, Edward M, additional, Drakaki, Alexandra, additional, Mannuel, Heather D, additional, Guancial, Elizabeth, additional, Fung, Chunkit, additional, Charles, Anthony, additional, Amato, Robert J, additional, Arriaga, Yull, additional, Bowman, Isaac, additional, Ades, Steven, additional, Dreicer, Robert, additional, Yu, Evan, additional, Quinn, David I, additional, and Fleming, Mark, additional

Published
2021
Full Text
View/download PDF

66. Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy.

Author

Ardeshirrouhanifard, Shirin, primary, Dinh, Paul C, additional, Monahan, Patrick O., additional, Fosså, Sophie, additional, Huddart, Robert A, additional, Fung, Chunkit, additional, Song, Yiqing, additional, Feldman, Darren R., additional, Hamilton, Robert James, additional, Vaughn, David J., additional, Martin, Neil E., additional, Kollmannsberger, Christian K., additional, Hou, Lifang, additional, Einhorn, Lawrence, additional, Kroenke, Kurt, additional, and Travis, Lois B., additional

Published
2021
Full Text
View/download PDF

67. Identifying gaps in the coverage of survivorship care services.

Author

Blaes, Anne Hudson, primary, Abu-Khalaf, Maysa M., additional, Bender, Catherine M., additional, Dent, Susan Faye, additional, Fung, Chunkit, additional, Smith, Sophia Kustas, additional, Watson, Samantha, additional, Katta, Sweatha, additional, Merrill, Janette K., additional, and Hudson, Shawna V., additional

Published
2021
Full Text
View/download PDF

68. A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.

Author

Kilari, Deepak, primary, Szabo, Aniko, additional, Bylow, Kathryn A., additional, Alter, Robert S., additional, Nelson, Ariel Ann, additional, Lemke, Emily, additional, Hall, William Adrian, additional, Johnson, Scott, additional, Langenstroer, Peter, additional, Jacobsohn, Kenneth, additional, Davis, Nancy B., additional, Fung, Chunkit, additional, and Milowsky, Matthew I., additional

Published
2021
Full Text
View/download PDF

69. Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.

Author

Shuey, Megan, primary, Faucon, Annika, additional, Trendowski, Matthew R., additional, Ratain, Mark J., additional, Dinh, Paul C, additional, Feldman, Darren R., additional, Hamilton, Robert James, additional, Vaughn, David J., additional, Fung, Chunkit, additional, Kollmannsberger, Christian K., additional, Huddart, Robert A, additional, Martin, Neil E., additional, Hannigan, Robyn, additional, Einhorn, Lawrence H., additional, Travis, Lois B., additional, Dolan, M. Eileen, additional, and Cox, Nancy, additional

Published
2021
Full Text
View/download PDF

70. Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.

Author

Ardeshirrouhanifard, Shirin, primary, Fosså, Sophie, additional, Huddart, Robert A, additional, Monahan, Patrick O., additional, Fung, Chunkit, additional, Song, Yiqing, additional, Dolan, M. Eileen, additional, Feldman, Darren R., additional, Hamilton, Robert James, additional, Vaughn, David J., additional, Martin, Neil E., additional, Kollmannsberger, Christian K., additional, Dinh, Paul C, additional, Hou, Lifang, additional, Zheng, Yinan, additional, Einhorn, Lawrence, additional, Frisina, Robert D., additional, and Travis, Lois B., additional

Published
2021
Full Text
View/download PDF

71. Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.

Author

Zhang, Xindi, Trendowski, Matthew R., Wilkinson, Emma, Shahbazi, Mohammad, Dinh, Paul C., Shuey, Megan M., Feldman, Darren R., Hamilton, Robert J., Vaughn, David J., Fung, Chunkit, Kollmannsberger, Christian, Huddart, Robert, Martin, Neil E., Sanchez, Victoria A., Frisina, Robert D., Einhorn, Lawrence H., Cox, Nancy J., Travis, Lois B., and Dolan, M. Eileen

Subjects
TINNITUS, HEARING disorders, TESTICULAR cancer, PERIPHERAL neuropathy, PHARMACOGENOMICS, GENOME-wide association studies, GERM cell tumors, TUMOR suppressor genes
Abstract

Purpose: Cisplatin is a critical component of first‐line chemotherapy for several cancers, but causes peripheral sensory neuropathy, hearing loss, and tinnitus. We aimed to identify comorbidities for cisplatin‐induced neurotoxicities among large numbers of similarly treated patients without the confounding effect of cranial radiotherapy. Methods: Utilizing linear and logistic regression analyses on 1680 well‐characterized cisplatin‐treated testicular cancer survivors, we analyzed associations of hearing loss, tinnitus, and peripheral neuropathy with nongenetic comorbidities. Genome‐wide association studies and gene‐based analyses were performed on each phenotype. Results: Hearing loss, tinnitus, and peripheral neuropathy, accounting for age and cisplatin dose, were interdependent. Survivors with these neurotoxicities experienced more hypertension and poorer self‐reported health. In addition, hearing loss was positively associated with BMIs at clinical evaluation and nonwork‐related noise exposure (>5 h/week). Tinnitus was positively associated with tobacco use, hypercholesterolemia, and noise exposure. We observed positive associations between peripheral neuropathy and persistent vertigo, tobacco use, and excess alcohol consumption. Hearing loss and TXNRD1, which plays a key role in redox regulation, showed borderline significance (p = 4.2 × 10−6) in gene‐based analysis. rs62283056 in WFS1 previously found to be significantly associated with hearing loss (n = 511), was marginally significant in an independent replication cohort (p = 0.06; n = 606). Gene‐based analyses identified significant associations between tinnitus and WNT8A (p = 2.5 × 10−6), encoding a signaling protein important in germ cell tumors. Conclusions: Genetics variants in TXNRD1 and WNT8A are notable risk factors for hearing loss and tinnitus, respectively. Future studies should investigate these genes and if replicated, identify their potential impact on preventive strategies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

72. Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study

Author

ArdeshirRouhaniFard, Shirin, primary, Dinh, Paul C., additional, Monahan, Patrick O., additional, Fossa, Sophie D., additional, Huddart, Robert, additional, Fung, Chunkit, additional, Song, Yiqing, additional, Feldman, Darren R., additional, Hamilton, Robert J., additional, Vaughn, David J., additional, Martin, Neil E., additional, Kollmannsberger, Christian, additional, Einhorn, Lawrence, additional, Kroenke, Kurt, additional, and Travis, Lois B., additional

Published
2021
Full Text
View/download PDF

75. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors

Author

Trendowski, Matthew R., primary, Wheeler, Heather E., additional, El-Charif, Omar, additional, Feldman, Darren R., additional, Hamilton, Robert J., additional, Vaughn, David J., additional, Fung, Chunkit, additional, Kollmannsberger, Christian, additional, Einhorn, Lawrence H., additional, Travis, Lois B., additional, and Dolan, M. Eileen, additional

Published
2020
Full Text
View/download PDF

78. Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors

Author

Kerns, Sarah L, primary, Fung, Chunkit, additional, Fossa, Sophie D, additional, Dinh, Paul C, additional, Monahan, Patrick, additional, Sesso, Howard D, additional, Frisina, Robert D, additional, Feldman, Darren R, additional, Hamilton, Robert J, additional, Vaughn, David, additional, Martin, Neil, additional, Huddart, Robert, additional, Kollmannsberger, Christian, additional, Sahasrabudhe, Deepak, additional, Ardeshir-Rouhani-Fard, Shirin, additional, Einhorn, Lawrence, additional, and Travis, Lois B, additional

Published
2020
Full Text
View/download PDF

81. Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors

Author

Fung, Chunkit, Dinh, PaulJr., Ardeshir-Rouhani-Fard, Shirin, Schaffer, Kerry, Fossa, Sophie D., and Travis, Lois B.

Subjects
Article Subject
Abstract

Testicular cancer has become the paradigm of adult-onset cancer survivorship, due to the young age at diagnosis and 10-year relative survival of 95%. This clinical review presents the current status of various treatment-related complications experienced by long-term testicular cancer survivors (TCS) free of disease for 5 or more years after primary treatment. Cardiovascular disease and second malignant neoplasms represent the most common potentially life-threatening late effects. Other long-term adverse outcomes include neuro- and ototoxicity, pulmonary complications, nephrotoxicity, hypogonadism, infertility, and avascular necrosis. Future research efforts should focus on delineation of the genetic underpinning of these long-term toxicities to understand their biologic basis and etiopathogenetic pathways, with the goal of developing targeted prevention and intervention strategies to optimize risk-based care and minimize chronic morbidities. In the interim, health care providers should advise TCS to adhere to national guidelines for the management of cardiovascular disease risk factors, as well as to adopt behaviors consistent with a healthy lifestyle, including smoking cessation, a balanced diet, and a moderate to vigorous intensity exercise program. TCS should also follow national guidelines for cancer screening as currently applied to the general population.

Published
2018
Full Text
View/download PDF

83. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy

Author

Trendowski, Matthew R., primary, El-Charif, Omar, additional, Ratain, Mark J., additional, Monahan, Patrick, additional, Mu, Zepeng, additional, Wheeler, Heather E., additional, Dinh, Paul C., additional, Feldman, Darren R., additional, Ardeshir-Rouhani-Fard, Shirin, additional, Hamilton, Robert J., additional, Vaughn, David J., additional, Fung, Chunkit, additional, Kollmannsberger, Christian, additional, Mushiroda, Taisei, additional, Kubo, Michiaki, additional, Hannigan, Robyn, additional, Strathmann, Frederick, additional, Einhorn, Lawrence H., additional, Fossa, Sophie D., additional, Travis, Lois B., additional, and Dolan, M. Eileen, additional

Published
2019
Full Text
View/download PDF

84. Abstract 3904: Pharmacokinetic modeling of serum platinum reveals extent of long-term exposure and associated comorbidities after cisplatin treatment

Author

Trendowski, Matthew R., primary, El-Charif, Omar, additional, Mu, Zepeng, additional, Ratain, Mark J., additional, Wheeler, Heather, additional, Dinh, Paul C., additional, Feldman, Darren R., additional, Ardeshir-Rouhani-Fard, Shirin, additional, Hamilton, Robert J., additional, Vaughn, David J., additional, Fung, Chunkit, additional, Mushiroda, Taisei, additional, Einhorn, Lawrence H., additional, Travis, Lois B., additional, and Dolan, M. Eileen, additional

Published
2019
Full Text
View/download PDF

85. Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer.

Author

Lin, Po-Ju, primary, Loh, Kah Poh, additional, Inglis, Julia Ellen, additional, Dunne, Richard Francis, additional, Kleckner, Ian, additional, Fung, Chunkit, additional, Gilmore, Nikesha, additional, Lopez, Gilberto, additional, Heckler, Charles E., additional, Culakova, Eva, additional, Peppone, Luke Joseph, additional, Janelsins, Michelle Christine, additional, Kamen, Charles Stewart, additional, and Mustian, Karen Michelle, additional

Published
2019
Full Text
View/download PDF

87. Evaluating the effects of a structured exercise intervention on physical self-worth in men with prostate cancer: Addressing an unmet need.

Author

Dunne, Richard Francis, primary, Heckler, Charles E., additional, Inglis, Julia Ellen, additional, Lin, Po-Ju, additional, Fung, Chunkit, additional, Peppone, Luke Joseph, additional, Lopez, Gilberto, additional, Culakova, Eva, additional, Kleckner, Ian, additional, Janelsins, Michelle Christine, additional, Jatoi, Aminah, additional, Mohile, Supriya Gupta, additional, and Mustian, Karen Michelle, additional

Published
2019
Full Text
View/download PDF

88. A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Tolerability and geriatric asssessment (GA) results.

Author

Zittel, Jason, primary, Fung, Chunkit, additional, Babu, Dilip Sankar, additional, Guancial, Elizabeth A., additional, Sahasrabudhe, Deepak M., additional, Bylow, Kathryn A., additional, Burfeind, John D., additional, Musto, Kaylinn, additional, Wang, Bokai, additional, Patil, Amita, additional, Messing, Edward M., additional, Mohile, Supriya Gupta, additional, and Kilari, Deepak, additional

Published
2019
Full Text
View/download PDF

89. The effect of structured exercise during chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN): A role for interoceptive brain circuitry.

Author

Kleckner, Ian, primary, Gewandter, Jennifer S., additional, Heckler, Charles E., additional, Staples, Susan, additional, Colasurdo, Ann, additional, Lin, Po-Ju, additional, Shayne, Michelle, additional, Huston, Alissa, additional, Magnuson, Allison, additional, Tejani, Mohamedtaki Abdulaziz, additional, Dunne, Richard Francis, additional, Fung, Chunkit, additional, Lipe, Brea, additional, Passero, Frank Charles, additional, Mohile, Nimish, additional, Morrow, Gary R., additional, Janelsins, Michelle Christine, additional, and Mustian, Karen Michelle, additional

Published
2019
Full Text
View/download PDF

91. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors

Author

Abu Zaid, Mohammad, primary, Dinh, Paul C., additional, Monahan, Patrick O., additional, Fung, Chunkit, additional, El-Charif, Omar, additional, Feldman, Darren R., additional, Hamilton, Robert J., additional, Vaughn, David J., additional, Beard, Clair J., additional, Cook, Ryan, additional, Althouse, Sandra, additional, Ardeshir-Rouhani-Fard, Shirin, additional, Sesso, Howard D., additional, Huddart, Robert, additional, Mushiroda, Taisei, additional, Kubo, Michiaki, additional, Dolan, M. Eileen, additional, Einhorn, Lawrence H., additional, Fossa, Sophie D., additional, Travis, Lois B., additional, and _, _, additional

Published
2019
Full Text
View/download PDF

92. Effects of a Home‐based Exercise Program on Anxiety and Mood Disturbances in Older Adults with Cancer Receiving Chemotherapy

Author

Loh, Kah Poh, primary, Kleckner, Ian R., additional, Lin, Po‐Ju, additional, Mohile, Supriya G., additional, Canin, Beverly E., additional, Flannery, Marie A., additional, Fung, Chunkit, additional, Dunne, Richard F., additional, Bautista, Javier, additional, Culakova, Eva, additional, Kleckner, Amber S., additional, Peppone, Luke J., additional, Janelsins, Michelle, additional, McHugh, Colin, additional, Conlin, Alison, additional, Cho, Jonathan K., additional, Kasbari, Sameer, additional, Esparaz, Benjamin T., additional, Kuebler, J. Philip, additional, and Mustian, Karen M., additional

Published
2019
Full Text
View/download PDF

93. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms

Author

El Charif, Omar, primary, Mapes, Brandon, additional, Trendowski, Matthew R., additional, Wheeler, Heather E., additional, Wing, Claudia, additional, Dinh, Paul C., additional, Frisina, Robert D., additional, Feldman, Darren R., additional, Hamilton, Robert J., additional, Vaughn, David J., additional, Fung, Chunkit, additional, Kollmannsberger, Christian, additional, Mushiroda, Taisei, additional, Kubo, Michiaki, additional, Gamazon, Eric R., additional, Cox, Nancy J., additional, Huddart, Robert, additional, Ardeshir-Rouhani-Fard, Shirin, additional, Monahan, Patrick, additional, Fossa, Sophie D., additional, Einhorn, Lawrence H., additional, Travis, Lois B., additional, and Dolan, M. Eileen, additional

Published
2019
Full Text
View/download PDF

94. Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial

Author

Kleckner, Ian R., primary, Kamen, Charles, additional, Cole, Calvin, additional, Fung, Chunkit, additional, Heckler, Charles E., additional, Guido, Joseph J., additional, Culakova, Eva, additional, Onitilo, Adedayo A., additional, Conlin, Alison, additional, Kuebler, J. Philip, additional, Mohile, Supriya, additional, Janelsins, Michelle, additional, and Mustian, Karen M., additional

Published
2019
Full Text
View/download PDF

96. Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer

Author

Osterman, Chelsea K., primary, Babu, Dilip S., additional, Geynisman, Daniel M., additional, Lewis, Bianca, additional, Somer, Robert A., additional, Balar, Arjun V., additional, Zibelman, Matthew R., additional, Guancial, Elizabeth A., additional, Antinori, Gianna, additional, Yu, Shun, additional, Narayan, Vivek, additional, Guzzo, Thomas J., additional, Plimack, Elizabeth R., additional, Vaughn, David J., additional, Fung, Chunkit, additional, and Mamtani, Ronac, additional

Published
2019
Full Text
View/download PDF

97. Systematic Review of Randomized Controlled Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer

Author

Schaffer, Kerry, primary, Panneerselvam, Narmadha, additional, Loh, Kah Poh, additional, Herrmann, Rachel, additional, Kleckner, Ian R., additional, Dunne, Richard Francis, additional, Lin, Po-Ju, additional, Heckler, Charles E., additional, Gerbino, Nicholas, additional, Bruckner, Lauren B., additional, Storozynsky, Eugene, additional, Ky, Bonnie, additional, Baran, Andrea, additional, Mohile, Supriya Gupta, additional, Mustian, Karen Michelle, additional, and Fung, Chunkit, additional

Published
2019
Full Text
View/download PDF

98. Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management.

Author

Agrawal, Vaibhav, Dinh, Paul C, Fung, Chunkit, Monahan, Patrick O, Althouse, Sandra K, Norton, Kelli, Cary, Clint, Einhorn, Lawrence, Fossa, Sophie D, Adra, Nabil, and Travis, Lois B

Subjects
ADVERSE health care events, TESTICULAR cancer treatment, CISPLATIN, CANCER chemotherapy, OPERATIVE surgery, CANCER patients, TESTICULAR cancer
Abstract

We evaluated for the first time, to our knowledge, adverse health outcomes (AHOs) among US testicular cancer survivors (TCS) given chemotherapy (n = 381) vs surgery-only patients (n = 98) managed at a single institution, accounting for non-treatment-related risk factors to delineate chemotherapy's impact. Chemotherapy consisted largely of bleomycin-etoposide-cisplatin (BEP) administered in three or four cycles (BEPx3, n = 235; BEPx4, n = 82). Incidence of at least 3 AHOs was lowest in surgery-only TCS and increased with BEPx3, BEPx4, and other cisplatin-based regimens (12.2%, 40.8%, 52.5%, 54.8%; P  <  .0001). Multivariable modeling assessed associations of risk factors and treatment with hearing impairment, tinnitus, peripheral neuropathy, and Raynaud phenomenon. Risk for each AHO statistically increased with both increasing chemotherapy burden (P  < .0001) and selected modifiable risk factors (P  < .05): hypertension (odds ratio [OR] = 2.40) and noise exposure (OR ≥ 2.3) for hearing impairment; noise exposure for tinnitus (OR ≥ 1.69); peripheral vascular disease for neuropathy (OR = 8.72); and current smoking for Raynaud phenomenon (OR = 2.41). Clinicians should manage modifiable risk factors for AHOs among TCS. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

99. Response to Crevenna and Ashbury, Vallance and Bolam, and Crevenna and Keilani regarding the effects of exercise on chemotherapy-induced peripheral neuropathy

Author

Kleckner, Ian R., primary, Kamen, Charles, additional, Gewandter, Jennifer S., additional, Mohile, Nimish A., additional, Heckler, Charles E., additional, Culakova, Eva, additional, Fung, Chunkit, additional, Janelsins, Michelle C., additional, Asare, Matthew, additional, Lin, Po-Ju, additional, Reddy, Pavan S., additional, Giguere, Jeffrey, additional, Berenberg, Jeffrey, additional, Kesler, Shelli R., additional, and Mustian, Karen M., additional

Published
2018
Full Text
View/download PDF

100. A Festschrift in Honor of Edward M. Messing, MD, FACS

Author

Joseph, Jean V., primary, Brasacchio, Ralph, additional, Fung, Chunkit, additional, Reeder, Jay, additional, Bylund, Kevin, additional, Sahasrabudhe, Deepak, additional, Yeh, Shu Yuan, additional, Ghazi, Ahmed, additional, Fultz, Patrick, additional, Rubens, Deborah, additional, Wu, Guan, additional, Singer, Eric, additional, Schwarz, Edward, additional, Mohile, Supriya, additional, Mohler, James, additional, Theodorescu, Dan, additional, Lee, Yi Fen, additional, Okunieff, Paul, additional, McConkey, David, additional, Rashid, Hani, additional, Chang, Chawnshang, additional, Fradet, Yves, additional, Guru, Khurshid, additional, Kukreja, Janet, additional, Sufrin, Gerald, additional, Lotan, Yair, additional, Bailey, Howard, additional, Noyes, Katia, additional, Schwartz, Seymour, additional, Rideout, Kathy, additional, Bratslavsky, Gennady, additional, Campbell, Steven C., additional, Derweesh, Ithaar, additional, Abrahamsson, Per-Anders, additional, Soloway, Mark, additional, Gomella, Leonard, additional, Golijanin, Dragan, additional, Svatek, Robert, additional, Frye, Thomas, additional, Lerner, Seth, additional, Palapattu, Ganesh, additional, Wilding, George, additional, Droller, Michael, additional, and Trump, Donald, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results